137- Converse RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic
overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912–8. - Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal
disease. Hypertension. 2004;43(4):699–706. - Ye S, Zhong H, Duong VN, Campese VM. Losartan reduces central and peripheral sympathetic
nerve activity in a rat model of neurogenic hypertension. Hypertension. 2002;39(6):1101–6. - Richter CM. Role of endothelin in chronic renal failure—developments in renal involvement.
Rheumatology (Oxford). 2006;45(Suppl 3):iii36–8. - Dunn MJ, Hood VL. Prostaglandins and the kidney. Am J Phys. 1977;233(3):169–84.
- Kone BC, Baylis C. Biosynthesis and homeostatic roles of nitric oxide in the normal kidney.
Am J Phys. 1997;272(5 Pt 2):F561–78. - Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis.
2001;38(4 Suppl 1):S74–9. - Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble monoamine
oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005;115(5):1275–80. - Desir GV. Regulation of blood pressure and cardiovascular function by renalase. Kidney Int.
2009;76(4):366–70. - Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, et al. Serum uric
acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communi-
ties study. Hypertension. 2006;48(6):1037–42. - Menè P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal dis-
ease? J Hypertens. 2008;26(11):2085–92. - Kuriyama S, Maruyama Y, Nishio S, Takahashi Y, Kidoguchi S, Kobayashi C, et al. Serum uric
acid and the incidence of CKD and hypertension. Clin Exp Nephrol. 2015;19(6):1127–34. - Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med.
2008;359(17):1811–21. - Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and
hypertension. Curr Opin Nephrol Hypertens. 2004;13(1):93–9. - Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH. Pathogenesis of calci-
neurin inhibitor-induced hypertension. J Nephrol. 2012;25(3):269–75. - Esteva-Font C, Ars E, Guillen-Gomez E, Campistol JM, Sanz L, Jiménez W, et al. Ciclosporin-
induced hypertension is associated with increased sodium transporter of the loop of Henle
(NKCC2). Nephrol Dial Transplant. 2007;22(10):2810–6. - Boyle SM, Berns JS. Erythropoietin and resistant hypertension in CKD. Semin Nephrol.
2014;34(5):540–9. - Touyz RM. New insights into mechanisms of hypertension. Curr Opin Nephrol Hypertens.
2012;21(2):119–21.
8 Pathophysiological Insights of Hypertension in Patients with Chronic Kidney Disease